FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060270856> ?p ?o ?g. }

• W2060270856 endingPage "S22" @default.
• W2060270856 startingPage "S16" @default.
• W2060270856 abstract "Pemetrexed (Alimta; Eli Lilly and Co, Indianapolis, IN) is a multitargeted antifolate that inhibits several folate-dependent enzymes that play roles in purine and pyrimidine synthesis. The principal toxicities of pemetrexed are neutropenia, diarrhea, nausea/vomiting, mucositis, and skin rash. These toxicities are more frequent in vitamin-deficient (folate and vitamin B 12 ) patients, and can be ameliorated by the co-administration of folate and vitamin B 12 . The use of prophylactic dexamethasone is also recommended to reduce the frequency of severe skin rash. Pemetrexed has significant single-agent activity in previously treated and untreated patients with non-small cell lung cancer (NSCLC). A recent phase III trial comparing pemetrexed with docetaxel in previously treated NSCLC patients showed equivalent efficacy with less bone marrow toxicity (eg, neutropenia) in the pemetrexed group. These results were pivotal in the approval of pemetrexed for the treatment of refractory NSCLC. Pemetrexed has been combined with the platinums (ie, cisplatin, carboplatin, and oxaliplatin) in NSCLC to yield clinical activity similar to that of other platinum-based doublets. A comparative phase III trial of cisplatin/pemetrexed against cisplatin/gemcitabine (Gemzar; Eli Lilly and Co) is under way. Pemetrexed has also been evaluated in combination with gemcitabine, and although the optimal dose and schedule of this combination has not been defined, clinical activity similar to other nonplatinum-based doublets has been observed. Preliminary evidence suggests that pemetrexed can be combined with thoracic radiation therapy, but more data are needed to evaluate the potential advantage(s) pemetrexed may have in this setting. Pemetrexed/platinum doublets also appear to possess activity in extensive stage small cell lung cancer. A phase II trial of single-agent pemetrexed is under way in both sensitive- and refractory-relapsed small cell lung cancer. Given the activity and excellent tolerability of pemetrexed, further studies in lung cancer are warranted." @default.
• W2060270856 created "2016-06-24" @default.
• W2060270856 creator A5014554706 @default.
• W2060270856 creator A5068906036 @default.
• W2060270856 creator A5078629724 @default.
• W2060270856 date "2005-04-01" @default.
• W2060270856 modified "2023-09-25" @default.
• W2060270856 title "The evolving role of pemetrexed (Alimta) in lung cancer" @default.
• W2060270856 cites W126814668 @default.
• W2060270856 cites W1797303364 @default.
• W2060270856 cites W1910732341 @default.
• W2060270856 cites W1988454321 @default.
• W2060270856 cites W1989088252 @default.
• W2060270856 cites W1996141967 @default.
• W2060270856 cites W2048394900 @default.
• W2060270856 cites W2074813517 @default.
• W2060270856 cites W2075327488 @default.
• W2060270856 cites W2102627969 @default.
• W2060270856 cites W2103662507 @default.
• W2060270856 cites W2110730246 @default.
• W2060270856 cites W2114998251 @default.
• W2060270856 cites W2134667653 @default.
• W2060270856 cites W2142703207 @default.
• W2060270856 cites W2145653040 @default.
• W2060270856 cites W2163379812 @default.
• W2060270856 cites W2223852752 @default.
• W2060270856 cites W2229928428 @default.
• W2060270856 cites W2244156441 @default.
• W2060270856 cites W2273112624 @default.
• W2060270856 cites W2281489950 @default.
• W2060270856 cites W2415007646 @default.
• W2060270856 cites W2466722221 @default.
• W2060270856 cites W2605111342 @default.
• W2060270856 cites W578327426 @default.
• W2060270856 doi "https://doi.org/10.1053/j.seminoncol.2005.02.008" @default.
• W2060270856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15818533" @default.
• W2060270856 hasPublicationYear "2005" @default.
• W2060270856 type Work @default.
• W2060270856 sameAs 2060270856 @default.
• W2060270856 citedByCount "12" @default.
• W2060270856 countsByYear W20602708562014 @default.
• W2060270856 countsByYear W20602708562016 @default.
• W2060270856 countsByYear W20602708562017 @default.
• W2060270856 countsByYear W20602708562018 @default.
• W2060270856 countsByYear W20602708562020 @default.
• W2060270856 crossrefType "journal-article" @default.
• W2060270856 hasAuthorship W2060270856A5014554706 @default.
• W2060270856 hasAuthorship W2060270856A5068906036 @default.
• W2060270856 hasAuthorship W2060270856A5078629724 @default.
• W2060270856 hasConcept C123321153 @default.
• W2060270856 hasConcept C126322002 @default.
• W2060270856 hasConcept C143998085 @default.
• W2060270856 hasConcept C2776256026 @default.
• W2060270856 hasConcept C2776694085 @default.
• W2060270856 hasConcept C2777063308 @default.
• W2060270856 hasConcept C2777240266 @default.
• W2060270856 hasConcept C2778239845 @default.
• W2060270856 hasConcept C2778570526 @default.
• W2060270856 hasConcept C2780258809 @default.
• W2060270856 hasConcept C2780350996 @default.
• W2060270856 hasConcept C2780456651 @default.
• W2060270856 hasConcept C2781190966 @default.
• W2060270856 hasConcept C2781451048 @default.
• W2060270856 hasConcept C71924100 @default.
• W2060270856 hasConcept C98274493 @default.
• W2060270856 hasConceptScore W2060270856C123321153 @default.
• W2060270856 hasConceptScore W2060270856C126322002 @default.
• W2060270856 hasConceptScore W2060270856C143998085 @default.
• W2060270856 hasConceptScore W2060270856C2776256026 @default.
• W2060270856 hasConceptScore W2060270856C2776694085 @default.
• W2060270856 hasConceptScore W2060270856C2777063308 @default.
• W2060270856 hasConceptScore W2060270856C2777240266 @default.
• W2060270856 hasConceptScore W2060270856C2778239845 @default.
• W2060270856 hasConceptScore W2060270856C2778570526 @default.
• W2060270856 hasConceptScore W2060270856C2780258809 @default.
• W2060270856 hasConceptScore W2060270856C2780350996 @default.
• W2060270856 hasConceptScore W2060270856C2780456651 @default.
• W2060270856 hasConceptScore W2060270856C2781190966 @default.
• W2060270856 hasConceptScore W2060270856C2781451048 @default.
• W2060270856 hasConceptScore W2060270856C71924100 @default.
• W2060270856 hasConceptScore W2060270856C98274493 @default.
• W2060270856 hasLocation W20602708561 @default.
• W2060270856 hasLocation W20602708562 @default.
• W2060270856 hasOpenAccess W2060270856 @default.
• W2060270856 hasPrimaryLocation W20602708561 @default.
• W2060270856 hasRelatedWork W1893184243 @default.
• W2060270856 hasRelatedWork W1967863863 @default.
• W2060270856 hasRelatedWork W2351358978 @default.
• W2060270856 hasRelatedWork W2383259583 @default.
• W2060270856 hasRelatedWork W2404692521 @default.
• W2060270856 hasRelatedWork W2439707001 @default.
• W2060270856 hasRelatedWork W2471989939 @default.
• W2060270856 hasRelatedWork W2477410415 @default.
• W2060270856 hasRelatedWork W2993175924 @default.
• W2060270856 hasRelatedWork W3127521146 @default.
• W2060270856 hasVolume "32" @default.
• W2060270856 isParatext "false" @default.
• W2060270856 isRetracted "false" @default.

• next